No effect of rosuvastatin on the pharmacokinetics of digoxin in healthy volunteers

Journal of Clinical Pharmacology

Volumn 42, Issue 12, 2002, Pages 1352-1357

  Martin, Paul D ^a   Kemp, John ^a   Dane, Aaron L ^a   Warwick, Mike J ^a   Schneck, Dennis W ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; ROSUVASTATIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASYSTOLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIGOXIN BLOOD LEVEL; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; KIDNEY CLEARANCE; MALE; MAXIMUM ALLOWABLE CONCENTRATION; NORMAL HUMAN; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL; STEADY STATE;

ADOLESCENT; ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; DIGOXIN; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PYRIMIDINES; SULFONAMIDES; TIME FACTORS;

EID: 0036891228     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270002042012008     Document Type: Article

References (14)

1. Olsson AG, Pears J, McKellar J, Mizan J, Raza A: Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol 2001;88(5):504-508.
2. Nezasa K, Takeuchi M, Yukawa T, Kawahara M, Inazawa K, Hasegawa H, et al: Tissue specific distribution of S-4522, a novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, to the liver in rats [abstract]. Xenobiotic Metab Dispos 1998;13(suppl.): S226.
3. Brown CDA, Windass A, Bleasby K, Lauffart B: Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C [abstract P174]. Atheroscler Suppl 2001;2(2):90.
4. McCormick AD, McKillop D, Butters CJ, Miles GS, Baba T, Touchi A, et al: ZD4522 - An HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: Metabolic studies in human in vitro systems [abstract 46]. J Clin Pharmacol 2000;40:1055.
5. Martin PD, Dane AL, Schneck DW, Warwick MJ: Disposition of new HMG-CoA reductase inhibitor ZD4522 following dosing in healthy subjects [abstract 48]. J Clin Pharmacol 2000;40:1056.
6. Boyd RA, Stern RH, Stewart BH, Wu X, Reyner EL, Zegarac EA, et al: Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol 2000;40(1):91-98.
7. Garnett WR, Venitz J, Wilkens RC, Dimenna G: Pharmacokinetic effects of fluvastatin in patients chronically receiving digoxin. Am J Med 1994;96(6A):84S-86S.
8. Hull CK, Penman AD, Smith CK, Martin PD: Quantification of rosuvastatin in human plasma by automated solid-phase extraction using tandem mass-spectrometric detection. J Chromatogr B Biomed Appl 2002;772:219-228.
9. Rameis H: The importance of prospective planning of pharmacokinetic trials: Considerations of studies on the phenytoin-digoxin-(P-D) and phenytoin-digitoxin-(P-DT) interaction. Int J Clin Pharmacol Ther Toxicol 1992;30(11):528-529.
10. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, et al: The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999;104(2):147-153.
11. Tanigawara Y, Okamura N, Hirai M, Yasuhara M, Ueda K, Kioka N, et al: Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J Pharmacol Exp Ther 1992;263(2):840-845.
12. Martin PD, Cooper KJ, Dane AL, Warwick MJ, Schneck DW, Nwose OM: Ketoconazole has no clinically relevant effect on the pharmacokinetics of rosuvastatin [abstract]. Pharmacol Toxicol 2001;89(suppl. 1):75.
13. Venkatakrishnan K, von Moltke LL, Greenblatt DJ: Effects of the antifungal agents on oxidative drug metabolism: Clinical relevance. Clin Pharmacokinet 2000;38(2):111-180.
14. Scripture CD, Pieper JA: Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet 2001;40(4):263-281.